A new "smart drug" may be effective in the treatment of metastatic triple negative breast cancer
-
Last Update: 2019-02-21
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Triple negative breast cancer is an invasive disease, which is more common in young women and African American women than other breast cancers Three negative breast cancer does not express estrogen receptor, progesterone receptor or HER2 Therefore, historically, treatment has included only chemotherapy for triple negative breast cancer, not targeted therapies such as hormone therapy or Herceptin According to a recent clinical trial published in the New England Journal of Medicine (http:// a new "smart drug" (http:// "has brought hope to women with metastatic triple negative breast cancer The drug, sacituzumab govitecan, is part of a new class of "smart drugs", which aims to provide toxic payloads directly to tumor cells The drug is a fusion of antibodies that recognize proteins expressed by breast cancer cells called trop2 and metabolites of the established chemotherapy drug (irinotecan) SN-38 The antibody delivered SN-38 directly to cancer cells The trial tested 108 women with metastatic triple negative breast cancer who had received two or more treatments Overall, 33% of patients responded to the drug; the median response duration was 7.7 months; the median overall survival was 13 months The main side effects found in the trial were hair loss, diarrhea and fatigue, but only 3% of patients had to stop taking the drug due to adverse events The drug is also tested in other types of breast, bladder and prostate cancer.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
